BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18176963)

  • 1. Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.
    Wakabayashi H; Nishiyama Y; Otani T; Sano T; Yachida S; Okano K; Izuishi K; Suzuki Y
    World J Gastroenterol; 2008 Jan; 14(1):64-9. PubMed ID: 18176963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival.
    Kim HR; Seo M; Nah YW; Park HW; Park SH
    Nucl Med Commun; 2018 Jul; 39(7):691-698. PubMed ID: 29893751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the management of patients with nonpancreatic periampullary neoplasms.
    Sperti C; Pasquali C; Fiore V; Bissoli S; Chierichetti F; Liessi G; Pedrazzoli S
    Am J Surg; 2006 Jun; 191(6):743-8. PubMed ID: 16720142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of 18F-fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma.
    Seo S; Doi R; Machimoto T; Kami K; Masui T; Hatano E; Ogawa K; Higashi T; Uemoto S
    J Hepatobiliary Pancreat Surg; 2008; 15(6):634-9. PubMed ID: 18987935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of 18F-FDG positron emission tomography/computed tomography on the pre-operative staging and the management of patients with pancreatic carcinoma.
    Wang XY; Yang F; Jin C; Guan YH; Zhang HW; Fu DL
    Hepatogastroenterology; 2014 Oct; 61(135):2102-9. PubMed ID: 25722999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
    Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
    HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours.
    Herrmann K; Erkan M; Dobritz M; Schuster T; Siveke JT; Beer AJ; Wester HJ; Schmid RM; Friess H; Schwaiger M; Kleeff J; Buck AK
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):846-51. PubMed ID: 22278320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy.
    Chang JS; Choi SH; Lee Y; Kim KH; Park JY; Song SY; Cho A; Yun M; Lee JD; Seong J
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):126-33. PubMed ID: 25015206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of pancreatic cancer using ¹⁸F-FDG PET/CT and CA19-9 with SUVmax association to clinical characteristics.
    Sun Y; Duan Q; Wang S; Zeng Y; Wu R
    J BUON; 2015; 20(2):452-9. PubMed ID: 26011335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Benefit of PET/CT in the preoperative staging in pancreatic carcinomas].
    Kysucan J; Lovecek M; Klos D; Tozzi I; Koranda P; Buriánková E; Neoral C; Havlík R
    Rozhl Chir; 2010 Aug; 89(7):433-40. PubMed ID: 20925260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.